INTRODUCTION

In the last decade, minimally invasive endovascular techniques have been established as a first-line strategy for the treatment of peripheral artery disease (PAD) [1]. Both femoropopliteal and below-the-knee (BTK) atherosclerotic
lesions are commonly treated with endovascular repair due to the lower 30-day morbidity and mortality reported, compared to bypass surgery [2,3]. Moreover, recent pooled data has shown satisfying limb salvage and overall survival rates using plain angioplasty (PTA) for BTK lesions, even in patients with critical limb ischemia (CLI) [4]. Randomized trials have also found an improved patency when using drug eluting stents in short isolated lesions, although the use of simple PTA or bare metal stents below the knee has shown rather disappointing results [5,6].

Another novel approach for longer and more difficult to treat lesions has been angioplasty with drug-coated balloons (DCBs). Several studies have shown that DCBs could improve patency and reduce target lesion revascularization (TLR) rates for femoropopliteal disease [7,8]. The delivery of paclitaxel directly to the arterial wall aims to inhibit neointimal hyperplasia and restenosis occurrence without the need for deployment of a foreign stent-material. However, early data regarding DCB for BTK lesions angioplasty has been inconsistent [9,10]. Additionally, data reporting on prognostic factors for major outcomes in such patients are limited. Therefore, aim of this study is to report major outcomes of DCB treatment in a series of patients with PAD, and to evaluate potential predictors for adverse events during follow-up.

**MATERIALS AND METHODS**

1) Study design

This was a retrospectively designed cohort study conducted in a Vascular Surgery Department at the Aristotle University of Thessaloniki (period of study: April 2013-April 2017). The study included patients with symptomatic PAD (Rutherford stage 1-6) that were treated with endovascular angioplasty using a paclitaxel-coated balloon, namely Lutonix (BARD Peripheral Vascular, Tempe, AZ, USA). All patients were classified according to the severity of chronic ischemia: patients with intermittent claudication (Rutherford stage 1-3) and patients with CLI (Rutherford Stage 4-6). CLI was defined as rest pain, ulcer or other necrotic lesions of the lower limb combined with an absolute arterial pressure of <50 mmHg at the anterior or posterior tibial arteries of the ipsilateral foot [1]. Data on treated vessel segment, the number, diameter and size of DCBs used, the need of additional stenting, predilatation was extracted from medical records.

Major outcomes included the following: overall mortality, overall amputation, major and minor amputation, clinical improvement, restenosis/re-occlusion, wound healing, TLR and hematoma/bleeding. Clinical improvement was defined as improvement of at least one Rutherford stage. Wound healing was defined as total ulcer healing or reduction of its size/depth. TLR was defined as any repeat angioplasty or other type of revascularization during follow-up. TLR was performed when the patient presented a restenosis or re-oclusion plus worsening of symptoms. Major amputation was defined as amputation at the level of the femur or the tibia. Minor amputation was defined as amputation at the level of the foot or the toes.

2) Procedure

The Lutonix DCB is a 0.000889 m (diameter), over-the-wire PTA dilation catheter with a semi-compliant balloon that is coated with paclitaxel at a concentration of 2 μg/mm2 and the excipients polysorbate and sorbitol to facilitate drug release and tissue deposition. The device diameters ranged 3-6 mm and the length 40-150 mm. All endovascular treatment decisions were at the discretion of the operator. When needed, predilatation with an undersized uncoated balloon (diameter >1 mm smaller) was performed before the DCB insertion. Minimum DCB inflation was 3 minutes. If multiple DCBs were needed to cover the entire lesion, an overlap of at least 5 mm had to be ensured. When significant recoil (>30%) occurred after DCB inflation or dissection was observed, stent deployment was performed.

3) Perioperative management

All patients were on a single antiplatelet regimen before the intervention (aspirin 100 mg or clopidogrel 75 mg/day). However, all patients received both agents for at least 3 days before repair or they received a loading dose of 300 mg clopidogrel in urgent cases. Additionally, each patient received a 70 units/kg bolus infusion of heparin during the procedure. Postoperatively, all patients received aspirin (100 mg/day) indefinitely plus clopidogrel (75 mg/day) for at least three months. If a stent was deployed, prolonged dual antiplatelet therapy could be given at the discretion of the physician. In patients with an indication for oral anticoagulation, addition of only 1 antiplatelet drug (either aspirin or clopidogrel) to the anticoagulant regimen was recommended. Before discharge, all patients underwent clinical examination and Doppler ultrasound evaluation. Regarding follow-up, all patients were scheduled for evaluation visits every 6 months after the procedure that included clinical and ultrasound evaluation.

4) Statistical analysis

Statistical analysis was conducted using the StatsDirect
Statistical ver. 2.8.0 software (StatsDirect Ltd., Cheshire, UK). Comparisons between groups were performed using the t-test for continuous variables and $\chi^2$ and Fisher exact tests for categorical variables as appropriate. Continuous data is presented as the means±standard deviation. Statistical significance was defined at a P-value of <0.05. The Kaplan-Meier method was used to estimate rates of overall mortality, freedom from major and minor amputation, restenosis/re-occlusion. Multivariate logistic regression was used to identify independent associations between various risk factors and major outcomes (death, all amputation, TLR).

This study was conducted according to the Helsinki Declaration for human rights. All patients provided a written informed consent.

This study was approved by the ethical committee of the Papageorgiou General Hospital, Thessaloniki (IRB no. 34563245).

**RESULTS**

Overall, 149 patients (159 limbs) were treated for IC (Group A, n=86) or CLI (Group B, n=63). Mean age of all patients was 68.6±8.3 years and the majority (113/149) were of male sex. Regarding basic demographics, the two groups were similar except for dyslipidemia (P=0.036) and diabetes mellitus (DM) (P=0.004) (Table 1). One fourth of the claudicants were of Stage 1-2, whereas 33 patients with CLI had an ulcer, 6 presented with rest pain and 24 patients presented with gangrene. The majority of atherosclerotic lesions were located in the femoropopliteal segment (81% of all lesions) and almost 40% of patients had a multilevel disease. In almost one third of cases, a stent needed to be deployed, whereas 76% of patients needed a predilatation. Predilatation was not associated with postdissection or stent deployment.

Mean diameter of balloons was 4.78 mm, mean length of balloons was 116.27 mm, and in 27.0% of cases, more than one device was needed. Patients with CLI presented more frequently with stenosis located in the popliteal artery (P=0.004), lesions of the infrapopliteal segment (stenosis: P=0.0001; occlusion: P=0.004), and with multilevel disease (P=0.00004). Moreover, patients with CLI needed predilatation (P=0.002) as well as the deployment of more than 1 DCB (P=0.040) more frequently (Table 2). Perioperative complications were limited. Only five patients presented a hematoma, without requiring further intervention. Additional, one patient presented atrial fibrillation on the 1st postoperative day, one patient presented acute myocardial infarction and one patient presented hematuria. Perioperative mortality was null. No evident embolization was observed.

The mean follow-up in this cohort was 24.2±2.3 months.

| Variable               | Total (n=149) | Claudicants (n=86) | CLI (n=63) | P-value |
|------------------------|--------------|-------------------|------------|---------|
| Age (y)                | 68.6±8.3     | 70.5±6.2          | 66.4±6.4   | 0.090   |
| Male                   | 113          | 70                | 43         | 0.080   |
| DM                     | 86           | 41                | 45         | 0.004   |
| Hypertension           | 106          | 64                | 42         | 0.460   |
| Dyslipidemia           | 71           | 46                | 25         | 0.036   |
| History of Smoking     | 97           | 61                | 36         | 0.590   |
| CAD                    | 41           | 24                | 17         | 0.990   |
| CKD                    | 7            | 4                 | 3          | 0.990   |
| COPD                   | 10           | 7                 | 3          | 0.520   |
| Rutherford classification | 22          | 22                | -          | -       |
| 1-2                    | 64           | 64                | -          | -       |
| 4                      | 6            | -                 | 6          |         |
| 5-6                    | 57           | -                 | 57         | -       |
| Ulcer                  | 33           | -                 | 33         | -       |
| Gangrene               | 24           | -                 | 24         | -       |
| Former procedures      | 38           | 21                | 17         | 0.850   |

Values are presented as mean±standard deviation or number only.
CLI, critical limb ischemia; DM, diabetes mellitus; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.
Former procedures refer to the target lesion.
During follow-up, 10.7% of patients died from various causes: cardiovascular death (n=11), infection (n=3), gastrointestinal bleeding (n=1), craniocerebral injury (n=1). Regarding amputation rate, 12 patients underwent major amputation and 16 patients underwent minor amputation. Overall, 99 patients (66.4%) showed clinical improvement during follow-up, and 27 patients with ulcer (81% of ulcers) showed signs of wound healing. Restenosis or re-occlusion was reported in 12 patients with 9 of them needing a TLR. Kaplan-Meier curves were generated for freedom from death, major amputation and TLR (Fig. 1).

When comparing the two groups during the follow-up period, patients with CLI were associated with a higher mortality rate (19.0% vs. 4.7%; P=0.007) and a higher all

Table 2. Type of lesion and procedure characteristics

| Variable                        | Total (n=149) | Claudicants (n=86) | CLI (n=63) | P-value |
|---------------------------------|---------------|--------------------|------------|---------|
| Type of lesion                  |               |                    |            |         |
| SFA stenosis                    | 93            | 57                 | 36         | 0.310   |
| SFA occlusion                   | 38            | 26                 | 12         | 0.130   |
| POP stenosis                    | 26            | 8                  | 18         | 0.004   |
| POP occlusion                   | 11            | 5                  | 6          | 0.530   |
| Infrapopliteal stenosis         | 26            | 1                  | 25         | 0.0001  |
| Infrapopliteal occlusion        | 12            | 2                  | 10         | 0.004   |
| Stent restenosis treated        | 14            | 10                 | 4          | 0.390   |
| Bypass stenosis                 | 2             | 2                  | 0          | 0.510   |
| Multilevel disease              | 60            | 24                 | 36         | 0.0004  |
| Procedure                       |               |                    |            |         |
| Only PTA                        | 109           | 58                 | 51         | 0.090   |
| Stenting                        | 40            | 27                 | 13         | 0.190   |
| Predilatation                   | 114           | 69                 | 35         | 0.002   |
| Mean diameter of balloons (mm)  | 4.78          | 5.11               | 4.34       | 0.140   |
| Mean length of balloons (mm)    | 116.27        | 120.63             | 113.71     | 0.090   |
| >1 DCB used (patients number)   | 43            | 19                 | 24         | 0.040   |
| Number of devices used (mean number) | 1.28   | 1.23               | 1.35       | 0.130   |
| Mean follow-up (mo)             | 24.2±2.3      | 25.1±1.8           | 23.3±2.1   | 0.080   |

Values are presented as number only or mean±standard deviation.

CLI, critical limb ischemia; SFA, superficial femoral artery; POP, popliteal artery; PTA, percutaneous transluminal angioplasty; DCB, drug-coated balloon.

Fig. 1. Kaplan-Meier curves of all patients (Total), claudicants (Clau) and patients with critical limb ischemia referring to: (A) overall survival, (B) freedom from major amputation, and (C) freedom from target lesion revascularization (TLR). CLI, critical limb ischemia.
amputation rate (44.4% vs. 0%; \( P=0.0001 \)). Moreover, claudicants were associated with a higher rate of clinical improvement (79.1% vs. 49.2%; \( P=0.0002 \)). However, no difference was found between the two groups as far as re-stenosis/re-occlusion and TLR rates are concerned (Table 3).

After conducting multi-regression analysis, the following risk factors were independently associated with death during follow-up: CAD (odds ratio [OR], 11.157; 95% confidence interval [CI], 2.054-60.592; \( P=0.005 \)), gangrene (OR, 3.671; 95% CI, 1.045-14.337; \( P=0.034 \)) and infrapopliteal disease (OR, 4.795; 95% CI, 1.043-22.051; \( P=0.044 \)). Additionally, CLI (OR, 19.705; 95% CI, 3.595-108.011; \( P=0.0006 \)) and gangrene (OR, 3.558; 95% CI, 1.852-7.675; \( P=0.034 \)) were independently associated with amputation during follow-up. However, none of the potential predictors evaluated did correlate with TLR during follow-up (Table 4).

**DISCUSSION**

This was a real world, single-center study on the treatment of lower limb occlusive disease using the Lutonix DCB. Outcomes were more favorable in patients with IC compared to CLI, as expected. However, this study also found certain prognostic factors for major outcomes in patients treated with DCBs.

Regarding perioperative outcomes, DCB angioplasty has shown promising results with minimal mortality and morbidity in our cohort. This concurs with literature where endovascular treatment in general has been associated with lower morbidity in patients with femoropopliteal disease compared to open surgery [11]. Hence, almost 80% of the lesions treated in our cohort were located in the femoropopliteal segment. However, pooled evidence comparing endovascular to open treatment for infrapopliteal disease or comparing DCB angioplasty to surgery in general are lacking.

Additionally, all-cause mortality and major amputation rates during a mean follow-up of almost 2 years were satisfying in our cohort, reaching 10.7% and 8.1%, respectively. In a recent study by Steiner et al. [12], combined major amputation and mortality rates reached 6.6% and 10.5% after a follow-up period of only 6 and 12 months, respectively. Moreover, the recent randomized trial LEVANT-2 has also found equally low mortality and major amputation rates within 12 months after treatment of femoropopliteal lesions with Lutonix balloon compared to simple angioplasty [13]. However, primary patency with DCB was found to be superior to conventional angioplasty within a 12-month follow-up in the former trial [13]. Finally, in a recent meta-analysis, DCBs were found to have lower TLR rates compared to PTA whereas the death risk was similar between the two methods [14]. Although our TLR rate is almost half of the rate reported in this meta-analysis, this could be justified as they reported 12-month rates and we report a mean 24-month results.

Pooled data have also been published comparing DCB treatment to bare-metal and drug-eluting stents for femoropopliteal disease. Katsanos et al. [15] have shown that vascular restenosis and TLR are significantly lower after DCB angioplasty compared to plain balloon angioplasty or bare-metal stenting, concurring with our results, where TLR was as low as 3.3% during follow-up. Additionally, DCBs showed no difference compared to drug-eluting stenting in the same review, as far as restenosis and TLR are concerned [16].

In the present study, we have evaluated potential predictors both for death and amputation during follow-up. Major predictors for death included CAD as well as the presence of gangrene or infrapopliteal disease, whereas CLI and gangrene were found to be associated with a higher amputation risk. Although large multicentre studies evaluating the Lutonix DCB for femoropopliteal disease have not evaluated potential risk predictors for adverse events, several smaller studies have found certain predictors for future restenosis and TLR [13,16]. Jang et al. [17] have found that major tis-

---

**Table 3. Outcomes for all patients, claudicants and CLI patients during follow-up**

| Outcome                        | Total (n=149) | Claudicants (n=86) | CLI (n=63) | P-value |
|--------------------------------|---------------|--------------------|------------|---------|
| All-cause mortality            | 16            | 4                  | 12         | 0.007   |
| All amputation                 | 28            | 0                  | 28         | 0.0001  |
| Major amputation               | 12            | 0                  | 12         | 0.0001  |
| Minor amputation               | 16            | 0                  | 16         | 0.0001  |
| Clinical improvement           | 99            | 68                 | 31         | 0.0002  |
| Wound/ulcer healing            | 27            | 0                  | 27         | 0.0001  |
| TLR                            | 5             | 3                  | 2          | 0.990   |
| Hematoma/bleeding              | 5             | 2                  | 3          | 0.990   |
| Restenosis/re-occlusion         | 12            | 6                  | 6          | 0.990   |

CLI, critical limb ischemia; TLR, target lesion revascularization.
### Table 4. Multiregression analysis

| Factor                  | Death                          | All amputation                   | TLR                                           |
|-------------------------|--------------------------------|----------------------------------|-----------------------------------------------|
|                         | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis |
|                         | OR (95% CI)    | P-value      | OR (95% CI)    | P-value      | OR (95% CI)    | P-value      | OR (95% CI)    | P-value      | OR (95% CI)    | P-value      |
| CLI                     | 5.915 (1.759-19.889) | 0.001 | 3.310 (0.605-18.113) | 0.168 | Infinity | <0.0001 | 19.705 (3.595-108.011) | 0.0006 | 0.825 (0.207-3.287) | 0.999 |
| DM                      | 0.942 (0.371-2.394) | 0.999 | - | - | - | - | - | - | 2.029 (0.428-9.619) | 0.373 |
| Hypertension            | 0.893 (0.329-2.416) | 1.000 | - | - | 1.104 (0.484-2.124) | 0.999 | - | - | 0.769 (0.194-3.045) | 0.709 |
| Dyslipidemia            | 1.099 (0.435-2.773) | 0.001 | 0.824 (0.419-1.619) | 0.676 | - | - | - | - | 0.796 (0.200-3.172) | 0.746 |
| History of smoking     | 1.072 (0.279-4.113) | 1.000 | 0.519 (0.233-1.127) | 0.096 | - | - | 0.392 (0.088-1.321) | 0.099 |
| CAD                     | 3.095 (1.282-7.473) | 0.002 | 11.157 (2.054-60.592) | 0.005 | 0.722 (0.284-1.834) | 0.494 | - | - | 0.722 (0.153-3.406) | 0.681 |
| CKD                     | 1.765 (0.672-4.785) | 0.078 | - | - | - | - | - | - | - | - |
| COPD                    | 2.709 (0.459-6.353) | 0.067 | - | - | - | - | - | - | - | - |
| Gangrene                | 5.208 (2.166-12.523) | 0.0008 | 3.671 (1.045-14.337) | 0.034 | 5.208 (2.863-9.474) | <0.0001 | 3.558 (1.852-7.675) | 0.034 | 3.000 (0.782-11.503) | 0.109 |
| Multilevel disease      | 1.483 (0.589-3.736) | 0.429 | - | - | 1.978 (1.009-3.877) | 0.049 | 0.443 (0.128-1.533) | 0.199 | 1.426 (0.375-5.416) | 0.603 |
| Infrapopliteal disease  | 2.921 (1.178-7.243) | 0.030 | 4.795 (1.043-22.051) | 0.044 | 2.532 (1.328-4.825) | 0.008 | 2.494 (0.708-8.787) | 0.155 | 0.933 (0.199-4.376) | 0.930 |
| Stenting                | - | - | - | - | 0.614 (0.222-1.699) | 0.347 | - | - | 0.366 (0.047-2.858) | 0.338 |

TLR, target lesion revascularization; OR, odds ratio; CI, confidence interval; CLI, critical limb ischemia; DM, diabetes mellitus; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.
sue loss (Rutherford class 6) and long length of lesion are associated with future restenosis although no association was found with TLR. Additionally, Schmidt et al. [18] have found that heavy calcification of lesion and obesity are both predictors for primary patency and TLR. However, no major predictors for TLR were observed in our cohort.

Regarding BTK disease, 25.5% of our patients were treated for infrapopliteal lesions, with infrapopliteal disease being independently associated with mortality. However, in other cohort studies, BTK disease was strongly associated with limb loss after endovascular-first approach for patients with CLI [19]. Moreover, Vierthaler et al. [20] have tried to evaluate in a large study of 1,244 patients to identify potential predictors of amputation after endovascular treatment for CLI and they did not find any association with the level of occlusive disease, concurring with our results. Furthermore, randomized trials have compared DCBs with plain balloon angioplasty for infrapopliteal lesions, as far as early and midterm outcomes are concerned. Concerning 30-day safety outcomes (cardiovascular events, amputations and TLR) as well as 6-month outcomes (patency loss and major amputations), DCB treatment did not show any difference with PTA in these trials [21]. Moreover, pooled data on infrapopliteal disease indicates that DCB treatment shows a similar one-year benefit with PTA as well [22]. Finally, pooled data also reveals similar clinical outcomes and angiographic efficacy during one-year follow-up after DCB treatment compared to drug-eluting stenting [23].

Moreover, CLI patients showed higher mortality and amputation rates as well as a lower clinical improvement rate during follow-up, as expected. This concurs with literature data showing that patients with CLI is associated with up to a 40% amputation rate at 6 months and 20%-25% mortality rate at one year after presentation [24,25]. This could be justified as CLI seems to be a systemic inflammatory condition associated with increased levels of circulating cytokines that may explain the worse prognosis [26]. Additionally, other authors have compared outcomes between these two patient groups and have reported controversial results. Todoran et al. [27] have found a higher mortality rate in CLI patients with femoropopliteal lesions compared to claudicans, although patency rates were similar between the two groups during follow-up. Conversely, Troccoli et al. [28] have found significantly lower patency rates in CLI patients compared to claudicans within one year of follow-up. However, most of comparative studies refer to patients treated with plain angioplasty, and comparative data on patients treated with DCBs are limited.

Limitations of this study include the small number of patients, and especially the low number of cases with infrapopliteal lesions. However, statistically significant associations were established. Second, the retrospective design of the study and the reliance on patient records are also major limitations. Third, the follow-up period is longer than one year but shorter than in some randomized trials. Additionally, single-institution series are often biased towards particular patient demographics and practice patterns, but these data represent the real-world application of DCBs. Finally, angiography was not routinely performed during follow-up, but only when a re-operation was necessary.

In conclusion, treatment with Lutonix DCB shows promising early and midterm results in patients with symptomatic PAD. Patients with CLI have clearly worse outcomes compared to patients with IC during follow-up, as expected. CAD, gangrene, CLI and infrapopliteal lesions seem to be independently associated with adverse outcomes, and therefore a closer observation is needed for such patients.

**REFERENCES**

1) Lumsden AB, Davies MG, Peden EK. Medical and endovascular management of critical limb ischemia. J Endovasc Ther 2009;16(2 Suppl 2):II:31-62.
2) Aihara H, Soga Y, Mii S, Okazaki J, Yamada T, Kamoi D, et al.; RECANALISE Registry Investigators. Comparison of long-term outcome after endovascular therapy versus bypass surgery in claudication patients with Trans-Atlantic Inter-Society Consensus-II C and D femoropopliteal disease. Circ J 2014;78:457-464.
3) Söderström MI, Arvela EM, Korhonen M, Halmesmäki KH, Albäck AN, Biancari F, et al. Infrapopliteal percutaneous transluminal angioplasty versus bypass surgery as first-line strategies in critical leg ischemia: a propensity score analysis. Ann Surg 2010;252:765-771.
4) Romiti M, Albers M, Brochado-Neto FC, Durazzo AE, Pereira CA, DeLucia N. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg 2008;47:975-981.
5) Bosiers M, Scheinert D, Peeters P, Torsello G, Zeller T, Deloose K, et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. J Vasc Surg 2012;55:390-398.
6) Scheinert D, Katsanos K, Zeller T,
Koppensteiner R, Commeau P, Bosiers M, et al. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J Am Coll Cardiol 2012;60:2290-2295.

7) Werk M, Albrecht T, Meyer DR, Ahmed MN, Behne A, Dietz U, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv 2012;5:831-840.

8) Scheinert D, Duda S, Zeller T, Kranenberg H, Ricke J, Bosiers M, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv 2014;7:10-19.

9) Schmidt A, Piorkowski M, Werner M, Ulrich M, Bausback Y, Bräunlich S, et al. First experience with drug-eluting balloons in infrapopliteal arteries: restenosis rate and clinical outcome. J Am Coll Cardiol 2011;58:1105-1109.

10) Liistro F, Porto I, Angioli P, Grotti S, Ricci L, Ducci K, et al. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia. Circulation 2013;128:615-621.

11) Antoniou GA, Chalmers N, Georgiadis GS, Lazarides MK, Antoniou SA, Serracino-Inglott F, et al. A meta-analysis of endovascular versus surgical reconstruction of femoropopliteal arterial disease. J Vasc Surg 2013;57:242-253.

12) Steiner S, Schmidt A, Bausback Y, Bräunlich S, Ulrich M, Banning-Eichenseer U, et al. Single-center experience with lutonix drug-coated balloons in infrapopliteal arteries. J Endovasc Ther 2016;23:417-423.

13) Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, et al; LEVANT 2 Investigators. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med 2015;373:145-153.

14) Giacoppo D, Cassese S, Harada Y, Colleran R, Michel J, Fusaro M, et al. Drug-coated balloon versus plain balloon angioplasty for the treatment of femoropopliteal artery disease: an updated systematic review and meta-analysis of randomized clinical trials. JACC Cardiovasc Interv 2016;9:1731-1742.

15) Katsanos K, Spiliopoulos S, Karamanithy N, Krokidis M, Sabharwal T, Taylor P. Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery. J Vasc Surg 2014;59:1123-1133.e8.

16) Thieme M, Von Bilderling P, Paetzel C, Karnabatidis D, Perez Delgado J, Lichtenberg M; Lutonix Global SFA Registry Investigators. The 24-month results of the lutonix global SFA registry: worldwide experience with lutonix drug-coated balloon. JACC Cardiovasc Interv 2017;10:1682-1690.

17) Jang SJ, Hsieh CA, Huang HL, Juang JM, Chou HH, Tsao CY, et al. Feasibility and clinical outcomes of peripheral drug-coated balloon in high-risk patients with femoropopliteal disease. PLoS One 2015;10:e0143658.

18) Schmidt A, Piorkowski M, Görner H, Steiner S, Bausback Y, Scheinert S, et al. Drug-coated balloons for complex femoropopliteal lesions: 2-year results of a real-world registry. JACC Cardiovasc Interv 2016;9:715-724.

19) Garg K, Kaszubska PA, Moridzadeh R, Rockman CB, Adelman MA, Maldonado TS, et al. Endovascular-first approach is not associated with worse amputation-free survival in appropriately selected patients with critical limb ischemia. J Vasc Surg 2014;59:392-399.

20) Vierthaler L, Callas PW, Goodney PP, Schanzer A, Patel VI, Cronenwett J, et al.; Vascular Study Group of New England. Determinants of survival and major amputation after peripheral endovascular intervention for critical limb ischemia. J Vasc Surg 2015;62:655-664.

21) Zeller T, Beschoner U, Pilger E, Bosiers M, Deloose K, Peeters P, et al. Paclitaxel-coated balloon in infrapopliteal arteries: 12-month results from the BIOLUX P-II randomized trial (BIOTRONIK’S-First in man study of the Passeo-18 LUX drug releasing PTA balloon catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries). JACC Cardiovasc Interv 2015;8:1614-1622.

22) Wu R, Tang S, Wang M, Li Z, Yao C, Wang S. Drug-eluting balloon versus standard percutaneous transulminal angioplasty in infrapopliteal arterial disease: a meta-analysis of randomized trials. Int J Surg 2016;35:88-94.

23) Cassese S, Ndrepepa G, Liistro F, Fanelli F, Kufner S, Ott I, et al. Drug-coated balloons for revascularization of infrapopliteal arteries: a meta-analysis of randomized trials. JACC Cardiovasc Interv 2016;9:1072-1080.

24) Westin GG, Armstrong EJ, Bang H, Yeo KK, Anderson D, Dawson DL, et al. Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. J Am Coll Cardiol 2014;63:682-690.

25) Varu VN, Hogg ME, Kibbe MR. Critical limb ischemia. J Vasc Surg 2010;51:230-241.

26) Jalkanen J, Maksimow M, Hollmén England. Determinants of survival and major amputation after peripheral endovascular intervention for critical limb ischemia. J Vasc Surg 2015;62:655-664.

27) Todoran TM, Connors G, Engelson BA, Sobieszczyk PS, Eisenhauer AC, Kinlay
S. Femoral artery percutaneous revascularization for patients with critical limb ischemia: outcomes compared to patients with claudication over 2.5 years. Vasc Med 2012;17:138-144.

Trocciola SM, Chaer R, Dayal R, Lin SC, Kumar N, Rhee J, et al. Comparison of results in endovascular interventions for infrainguinal lesions: claudication versus critical limb ischemia. Am Surg 2005;71:474-479; discussion 480.